329 related articles for article (PubMed ID: 19285635)
21. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG
Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897
[TBL] [Abstract][Full Text] [Related]
22. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.
Iori AP; Torelli GF; De Propris MS; Milano F; Pupella S; Gozzer M; Mancini F; Milani ML; Intoppa S; Cerretti R; Lucarelli B; Valle V; Malandruccolo L; Iannella E; Arleo E; Guarini A; Foà R
Transplantation; 2008 Feb; 85(3):386-90. PubMed ID: 18322430
[TBL] [Abstract][Full Text] [Related]
23. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.
Rajasekar R; Mathews V; Lakshmi KM; Sellathamby S; George B; Viswabandya A; Daniel D; Chandy M; Srivastava A
Biol Blood Marrow Transplant; 2008 Mar; 14(3):344-50. PubMed ID: 18275901
[TBL] [Abstract][Full Text] [Related]
24. Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome.
Sato T; Kobayashi R; Nakajima M; Iguchi A; Ariga T
Bone Marrow Transplant; 2005 Dec; 36(11):985-91. PubMed ID: 16184178
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
Talarn C; Urbano-Ispizua A; Martino R; Pérez-Simón JA; Batlle M; Herrera C; Granell M; Gaya A; Torrebadell M; Fernández-Avilés F; Aymerich M; Marín P; Sierra J; Montserrat E
Haematologica; 2007 Dec; 92(12):1655-63. PubMed ID: 18055989
[TBL] [Abstract][Full Text] [Related]
26. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
Larocca A; Piaggio G; Podestà M; Pitto A; Bruno B; Di Grazia C; Gualandi F; Occhini D; Raiola AM; Dominietto A; Bregante S; Lamparelli T; Tedone E; Oneto R; Frassoni F; Van Lint MT; Pogliani E; Bacigalupo A
Haematologica; 2006 Jul; 91(7):935-40. PubMed ID: 16818281
[TBL] [Abstract][Full Text] [Related]
27. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
[TBL] [Abstract][Full Text] [Related]
28. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
[TBL] [Abstract][Full Text] [Related]
29. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
[TBL] [Abstract][Full Text] [Related]
30. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
31. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).
Arora M; Nagaraj S; Wagner JE; Barker JN; Brunstein CG; Burns LJ; Defor TE; McMillan ML; Miller JS; Weisdorf DJ
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1145-52. PubMed ID: 17889350
[TBL] [Abstract][Full Text] [Related]
32. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
34. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
35. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
36. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
Jagasia M; Giglia J; Chinratanalab W; Dixon S; Chen H; Frangoul H; Engelhardt B; Goodman S; Greer J; Kassim A; Morgan D; Ruffner K; Schuening F
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1207-15. PubMed ID: 17889358
[TBL] [Abstract][Full Text] [Related]
37. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
38. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies.
Chang YJ; Zhao XY; Huo MR; Xu LP; Liu DH; Liu KY; Huang XJ
Am J Hematol; 2011 Feb; 86(2):227-30. PubMed ID: 21264916
[TBL] [Abstract][Full Text] [Related]
40. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset.
Sohn SK; Kim DH; Kim JG; Lee NY; Suh JS; Lee KS; Lee KB
Bone Marrow Transplant; 2004 Jul; 34(1):63-8. PubMed ID: 15133486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]